69,748 results match your criteria Systemic Lupus Erythematosus


Suppurative Cervical Adenitis Due to Streptococcus pneumoniae Infection in Systemic Lupus Erythematosus.

J Clin Rheumatol 2019 Apr 12. Epub 2019 Apr 12.

Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, The Pennsylvania State University College of Medicine, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000001035DOI Listing

The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity.

JCI Insight 2019 Apr 18;4(8). Epub 2019 Apr 18.

Department of Dermatology.

Autoimmune disease is 4 times more common in women than men. This bias is largely unexplained. Female skin is "autoimmunity prone," showing upregulation of many proinflammatory genes, even in healthy women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.127291DOI Listing

Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections.

Braz J Med Biol Res 2019 15;52(4):e8131. Epub 2019 Apr 15.

Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, People's Republic of China.

The leading cause of death in systemic lupus erythematosus (SLE) patients is infection. The objective of this study was to evaluate the distribution of lymphocyte subsets in untreated SLE patients with infections. This was a cross-sectional study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1414-431X20198131DOI Listing

All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013).

Ann Rheum Dis 2019 Apr 16. Epub 2019 Apr 16.

Center for Prognosis Studies in the Rheumatic Diseases, Toronto Lupus Clinic, University Health Network, University of Toronto, Toronto, Ontario, Canada

Background: Survival in systemic lupus erythematosus (SLE) has improved substantially in the last 50 years. The aim of the present study was to assess the evolution of the all-cause, cause-specific and age-specific standardised mortality ratios (SMRs) of patients with lupus in Ontario, Canada.

Patients And Methods: Between 1971 and 2013, 1732 patients were followed in the Toronto Lupus Clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214802DOI Listing

Living with systemic lupus erythematosus in South Africa: a bitter pill to swallow.

Health Qual Life Outcomes 2019 Apr 16;17(1):65. Epub 2019 Apr 16.

Rheumatic Disease Unit, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.

Background: Systemic lupus erythematosus (SLE) often has a profound negative impact on health-related quality of life (HRQoL). In the absence of any qualitative studies in sub-Saharan Africa, we undertook a study to explore living experiences, perceptions and unmet needs of South African patients with SLE.

Methods: Twenty-five women with SLE consented to participate in the study. Read More

View Article

Download full-text PDF

Source
https://hqlo.biomedcentral.com/articles/10.1186/s12955-019-1
Publisher Site
http://dx.doi.org/10.1186/s12955-019-1132-yDOI Listing
April 2019
1 Read

MiR-199-3p promotes ERK-mediated IL-10 production by targeting poly (ADP-ribose) Polymerase-1 in patients with systemic lupus erythematosus.

Chem Biol Interact 2019 Apr 13. Epub 2019 Apr 13.

Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, PR China. Electronic address:

MicroRNAs (miRNAs) have been implicated in both biological and pathological processes in patients with systemic lupus erythematosus (SLE). Previous studies have demonstrated dysregulated expression of miR-199-3p, interleukin (IL)-10, and poly (ADP-ribose) polymerase-1 (PARP-1) in SLE. However, the underlying mechanisms of these aberrations have not been fully elucidated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00092797183128
Publisher Site
http://dx.doi.org/10.1016/j.cbi.2019.04.015DOI Listing
April 2019
1 Read

Mortality in patients with systemic lupus erythematosus in Colombia: a case series.

Clin Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

GIRAT: Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional, Fundación Valle del Lili and Universidad Icesi, Cali, Colombia.

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with high mortality rates. This study aimed to describe the main causes of death in a case series of SLE patients attended in a single center in Colombia.

Methods: We conducted a retrospective review and analysis of records of SLE patients who died between January 2011 and June 2017. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10067-019-04546-w
Publisher Site
http://dx.doi.org/10.1007/s10067-019-04546-wDOI Listing
April 2019
1 Read

Examining Uncertainty in Illness in Parents and Children With Chronic Kidney Disease and Systemic Lupus Erythematosus: A Mediational Model of Internalizing Symptoms and Health-Related Quality of Life.

J Clin Psychol Med Settings 2019 Apr 15. Epub 2019 Apr 15.

Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia, 34th Street and Civic Center Blvd, Philadelphia, PA, 19104, USA.

To examine if parent illness uncertainty is indirectly associated with child depression, anxiety, and HRQOL in the CKD/SLE population. Parent-child dyads (N = 31) from outpatient rheumatology and nephrology clinics included children (ages 9-18) diagnosed with CKD (Stage 1, 2, or nephrotic syndrome) or SLE. Parents completed demographic and uncertainty measures and children completed uncertainty, depression, anxiety, and HRQOL measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10880-019-09617-3DOI Listing

Anti-IL-10 antibody in systemic lupus erythematosus.

Open Access Rheumatol 2019 26;11:61-65. Epub 2019 Mar 26.

Division of Rheumatology and Allergology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan,

Purpose: IL-10 is a cytokine known to inhibit inflammatory cytokines. To determine its role in the pathogenesis of systemic lupus erythematosus (SLE), the presence of anti-IL-10 antibody is required to be examined. Although antibodies against cytokines are known to be present in SLE, no studies have determined the role of IL-10, particularly in Japanese patients. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/anti-il-10-antibody-in-systemic-lu
Publisher Site
http://dx.doi.org/10.2147/OARRR.S191953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440452PMC
March 2019
1 Read

[Systemic Lupus Erythematosus].

Authors:
Tetsuya Tsuchida

Brain Nerve 2019 Apr;71(4):317-321

Department of Dermatology, Saitama Medical University.

The cutaneous manifestations of lupus erythematosus (LE) include LE-specific and LE-nonspecific skin lesions. LE-specific skin lesions are divided into chronic, subacute, and acute types. The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416201268DOI Listing

Construction of a frailty index as a novel health measure in systemic lupus erythematosus.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

Department of Medicine, Division of Rheumatology, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Community Health & Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada; Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea;Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico; Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA; Division of Rheumatology, CHU de Québec et Université Laval, Quebec City, Canada; Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, ON, Canada; Arthritis Research UK Epidemiology Unit, Faculty of Biology Medicine and Health, Manchester Academic Health Sciences Center, The University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Center Manchester, UK; Center for Rheumatology, Department of Medicine, University College London, UK; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, King's College London School of Medicine, UK, London, UK; Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA; Northwestern University and Feinberg School of Medicine, Chicago, IL, USA; Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA, USA; Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland UK; Feinstein Institute for Medical Research, Manhasset, NY, USA; Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain; Emory University School of Medicine, Division of Rheumatology, Atlanta, Georgia, USA Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey; Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden; Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden. Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain; Medical University of South Carolina, Charleston, South Carolina, USA; UCSD School of Medicine, La Jolla, CA, USA; Copenhagen Lupus and Vasculitis Clinic, 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; University of Manitoba, Winnipeg, Manitoba, Canada; Hospital for Joint Diseases, NYU, Seligman Center for Advanced Therapeutics, New York NY; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada. Funding for this work was provided by the Nova Scotia Health Authority Research Fund. Dr. Sang-Cheol Bae's work was supported in part by NRF-2017M3A9B4050335, Republic of Korea. Dr. Caroline Gordon's work was supported by Lupus UK and the NIHR /Wellcome Trust Clinical Research Facility. The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Paul R. Fortin presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Université Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is a National Institute for Health Research (NIHR) Senior Investigator and is supported by Arthritis Research UK, the NIHR Manchester Biomedical Centre and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Dr Isenberg and Dr Rahman are supported by and supported by the National Institute for Health, Research University College London Hospitals Biomedical Research Center. The Hopkins Lupus Cohort is supported by the NIH (grant AR43727 and 69572). Dr. Mary Anne Dooley's work was supported by the NIH (grant RR00046). Dr. Ramsey-Goldman's work was supported by the NIH (grants 5UL1TR001422-02, formerly 8UL1TR000150 and UL-1RR-025741, K24-AR-02318, and P60AR064464 formerly P60-AR- 48098). Dr. Ruiz-Irastorza is supported by the Department of Education, Universities and Research of the Basque Government. Dr. Soren Jacobsen is supported by the Danish Rheumatism Association (A3865) and the Novo Nordisk Foundation (A05990). Dr. John G. Hanly is supported by the Canadian Institutes of Health Research (grant MOP-88526). Address Correspondence to: Dr. John G Hanly, Division of Rheumatology, Nova Scotia Rehabilitation Centre (2nd Floor), 1341 Summer Street, Halifax, Nova Scotia, Canada, B3H 4K4.Email:

Objective: To construct a frailty index (FI) as a measure of vulnerability to adverse outcomes among patients with SLE, using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Methods: The SLICC inception cohort consists of recently diagnosed SLE patients followed annually with clinical and laboratory assessments. For this analysis, the baseline visit was defined as the first study visit at which sufficient information was available for construction of a frailty index. Read More

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.181338
Publisher Site
http://dx.doi.org/10.3899/jrheum.181338DOI Listing
April 2019
1 Read

Bacteremia in systemic lupus erythematosus patients from RELESSER: risk factors, clinical and microbiological characteristics and outcomes.

J Rheumatol 2019 Apr 15. Epub 2019 Apr 15.

This work was supported by the Spanish Foundation of Rheumatology. JMPR. is supported by grant 316265 (BIOCAPS) from the European Union 7th Framework Programme (FP7/ REGPOT-2012-2013.1) and FIS/ISCIII-Fondo Europeo de Desarrollo regional (FEDER) (Grant number PI11/02857). Address correspondence to Iñigo Rua-Figueroa Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín Bco. De La Ballena s/n 35011-Las Palmas de G. Canaria (Spain) Email:

Objective: To describe the incidence of bacteremia in a large multicentric cohort of SLE patients and their clinical characteristics and to identify risk factors.

Methods: All bacteremic episodes from the RELESSER registry were included. Clinical and laboratory characteristics concerning bacteremia and SLE status, as well as comorbidities at the time of infection, were retrospectively collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180882DOI Listing

Osmium-Labeled Microspheres for Bead-Based Assays in Mass Cytometry.

J Immunol 2019 Apr 15. Epub 2019 Apr 15.

German Rheumatism Research Centre Berlin, a Leibniz Institute, 10117 Berlin, Germany; and

Polystyrene beads are broadly applied in flow cytometry. Implementing bead-based assays in mass cytometry is desired but hampered by the lack of an elemental label required for their detection. In this study, we introduce stable osmium tetroxide labeling as a universal approach for generating functionalized beads readily detectable by mass cytometry. Read More

View Article

Download full-text PDF

Source
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1801640
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1801640DOI Listing
April 2019
1 Read

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

J Immunol 2019 Apr 15. Epub 2019 Apr 15.

Translational Innovation Platform Immunology, EMD Serono Research and Development Institute, Billerica, MA 01821; and

Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptormediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils. We evaluated evobrutinib in preclinical models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1800583DOI Listing

Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus.

Semin Arthritis Rheum 2019 Mar 16. Epub 2019 Mar 16.

Division of Rheumatology, Cincinnati Children's Hospital Medical Center, MLC 4010, 3333 Burnet Avenue, Cincinnati, OH 45229, USA. Electronic address:

Glucocorticoids are potent anti-inflammatory and immunosuppressant medications and remain the mainstay of systemic lupus erythematosus (SLE) therapy. The potency of a specific glucocorticoid, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2019.03.010DOI Listing

Thrombocytopenia as a Prognostic Marker for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis.

Am J Med Sci 2019 Mar 11. Epub 2019 Mar 11.

Department of Rheumatology and Immunology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

Background: Systemic lupus erythematosus (SLE) patients often exhibit hematological abnormalities, but the role of thrombocytopenia on the prognosis of SLE shows inconsistent results. The purpose of this meta-analysis was to confirm the impact of thrombocytopenia on mortality and end organ damage in patients with SLE.

Materials And Methods: Three electronic databases, PubMed, Embase and Cochrane library were systematically searched to identify the eligible studies from inception to November 2017 in order to evaluate the impact of thrombocytopenia on the prognosis of patients with SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjms.2019.03.002DOI Listing

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.

Expert Rev Clin Immunol 2019 Apr 16. Epub 2019 Apr 16.

a The First Department of Internal Medicine , University of Occupational and Environmental Health , Japan.

Introduction: JAK, which constitutively binds to some cytokine receptors, plays an important role in cytokine signaling. While JAK is comprised of JAK1, JAK2, JAK3, and Tyk2, more than 40 types of cytokines transmit signals through JAK. Baricitinib is reported to be highly effective in the treatment of rheumatoid arthritis (RA) and is the second drug launched as a JAK inhibitor for RA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1608821DOI Listing

Bilateral Orbital Compartment Syndrome Preceding Cerebellar Herniation in Neuropsychiatric Systemic Lupus Erythematosus.

Ophthalmic Plast Reconstr Surg 2019 Apr 9. Epub 2019 Apr 9.

Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, U.S.A.

Orbital compartment syndrome poses a significant risk for vision loss if not promptly treated. The authors report a patient with neuropsychiatric systemic lupus erythematosus presenting with bilateral orbital compartment syndrome and rapid decompensation leading to uncal and tonsillar herniation. While extremely rare, bilateral orbital compartment syndrome should prompt consideration of systemic etiologies including neuropsychiatric systemic lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0000000000001339DOI Listing

Interaction between IL-33 Gene Polymorphisms and Current Smoking with Susceptibility to Systemic Lupus Erythematosus.

J Immunol Res 2019 11;2019:1547578. Epub 2019 Mar 11.

Department of Epidemiology and Biostatistics, School of Public Health, Fudan University, Shanghai 200040, China.

Aims: This study is aimed at exploring the relation between IL-33 single-nucleotide polymorphisms (SNPs) and the risk of systemic lupus erythematosus (SLE).

Methods: SNPStats (online software) was used to test the Hardy-Weinberg equilibrium in controls. Generalized multifactor dimensionality reduction (GMDR) was adopted to screen the preferable interaction between IL-33 SNPs and current smoking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/1547578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432724PMC

Oral Antifungal Therapy: Emerging Culprits of Cutaneous Adverse Drug Reactions.

Indian Dermatol Online J 2019 Mar-Apr;10(2):125-130

Department of Dermatology, N.H.L. Medical College, Ahmedabad, Gujarat, India.

Introduction: Antifungals are one of the most widely used drugs in dermatology practice for dermatophytosis. Oral antifungal therapy against superficial dermatophytosis is generally associated with a low incidence of adverse events in an immunocompetent population. However, lately, cutaneous adverse drugs reactions (CADRs) have been reported with varying incidence rates in the patients on oral antifungal therapy with many uncommon morphological patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_353_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434756PMC
April 2019
2 Reads

HERVs, immunity, and autoimmunity: understanding the connection.

Authors:
Matthew Greenig

PeerJ 2019 5;7:e6711. Epub 2019 Apr 5.

Department of Life Sciences, Imperial College London, London, United Kingdom.

Since their discovery in the 1960s, further investigation into endogenous retroviruses (ERVs) has challenged the conventional view of viral sequences as exclusively parasitic elements. Once presumed to be a group of passive genetic relics, it is becoming increasingly clear that this view of ERVs, while generally accurate, is incorrect in many specific cases. Research has identified ERV genes that appear to be co-opted by their mammalian hosts, but the biological function of ERV elements in humans remains a controversial subject. Read More

View Article

Download full-text PDF

Source
https://peerj.com/articles/6711
Publisher Site
http://dx.doi.org/10.7717/peerj.6711DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452852PMC
April 2019
1 Read

Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases.

Autoimmune Dis 2019 11;2019:5350960. Epub 2019 Mar 11.

Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional (GIRAT), Fundación Valle del Lili and Universidad Icesi, Cali, Colombia.

Introduction: Autoimmune diseases include a diverse and complex group of pathologies with a broad clinical spectrum due to the production of autoantibodies, which generates multisystemic compromise. Therapeutic plasma exchange (TPE) is a good additive treatment for immunosuppression due to its action over the autoantibodies.

Objectives: To describe the main clinical characteristics and outcomes of patients with systemic lupus erythematosus and other systemic autoimmune diseases managed with TPE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5350960DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432729PMC

CD28 CD4 T-cell expansions in autoimmune disease suggest a link with cytomegalovirus infection.

F1000Res 2019 25;8. Epub 2019 Mar 25.

Department of Clinical and Experimental medicine, Brighton and Sussex Medical School, Brighton, Sussex, BN1 9PX, UK.

Immunosenescence is thought to contribute to the increase of autoimmune diseases in older people. Immunosenescence is often associated with the presence of an expanded population of CD4 T cells lacking expression of CD28 (CD28 ). These highly cytotoxic CD4 T cells were isolated from disease-affected tissues in patients with rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, or other chronic inflammatory diseases and their numbers appeared to be linked to disease severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.17119.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436193PMC

Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.

F1000Res 2019 25;8. Epub 2019 Mar 25.

Department of Dermatology, Corporal Michael J. Crescenz VAMC, 3900 Woodland Avenue, Philadelphia, PA 19104, USA.

Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can be associated with systemic lupus erythematosus (SLE) symptoms. The pathogenesis of both CLE and SLE is multifactorial, involving genetic susceptibility, environmental factors, and innate and adaptive immune responses. Despite the efficacy of current medications, many patients remain refractory, highlighting the necessity for new treatment options. Read More

View Article

Download full-text PDF

Source
https://f1000research.com/articles/8-332/v1
Publisher Site
http://dx.doi.org/10.12688/f1000research.17787.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436187PMC
March 2019
5 Reads

Mapping of Dynamic Transcriptome Changes Associated With Silica-Triggered Autoimmune Pathogenesis in the Lupus-Prone NZBWF1 Mouse.

Front Immunol 2019 29;10:632. Epub 2019 Mar 29.

Department of Food Science and Human Nutrition, Michigan State University, East Lansing, MI, United States.

Crystalline silica (cSiO) is a widely recognized environmental trigger of autoimmune disease. In the lupus-prone female NZBWF1 mouse, airway exposure to cSiO triggers pulmonary ectopic lymphoid neogenesis, systemic autoantibody elevation, and glomerulonephritis. Here we tested the hypothesis that upregulation of adaptive immune function genes in the lung precedes cSiO-triggering of autoimmune disease in this model. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00632
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450439PMC
March 2019
1 Read

Renal transplantation for lupus nephritis: non-adherence and graft survival.

Lupus 2019 Apr 13:961203319842641. Epub 2019 Apr 13.

1 Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom.

Objectives: Poor adherence to immunosuppressive treatment is common in patients with systemic lupus erythematosus and may identify those with lupus nephritis (LN) who have a poorer prognosis. Non-adherence has also been reported to be a potential adverse outcome predictor in renal transplantation (rTp). We investigated whether non-adherence is associated with increased rTp graft rejection and/or failure in patients with LN. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0961203319842641
Publisher Site
http://dx.doi.org/10.1177/0961203319842641DOI Listing
April 2019
1 Read

[Coronary involvement and nephrotic syndrome in systemic lupus: A case report].

Rev Med Interne 2019 Apr 10. Epub 2019 Apr 10.

Service de médecine interne 2, Centre national de référence maladies systémiques rares, lupus et syndrome des anticorps antiphospholipides, hôpital de la Pitié-Salpêtrière, Sorbonne université, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address:

Introduction: Heart failure during systemic lupus erythematosus has various causes.

Case Report: A 29-year-old female presented with a systemic lupus flare and a nephrotic syndrome, followed by cardiogenic shock requiring extra-corporeal membranous oxygenation. Ventricular dysfunction was related to massive myocardial infarction due to an anterior interventricular artery thrombosis and an underlying atheroma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S02488663193009
Publisher Site
http://dx.doi.org/10.1016/j.revmed.2019.03.001DOI Listing
April 2019
2 Reads

Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes.

Ann Rheum Dis 2019 Apr 12. Epub 2019 Apr 12.

Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Objectives: Cognitive dysfunction (CD) is common in systemic lupus erythematosus (SLE) but the cause remains unclear and treatment options are limited. We aimed to compare cognitive function in SLE and healthy controls (HCs) using both behavioural and neuroimaging techniques.

Methods: Patients with SLE with stable disease and HCs were recruited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2018-214677DOI Listing

Treatment Options for Refractory Lupus Nephritis.

Clin J Am Soc Nephrol 2019 Apr 12. Epub 2019 Apr 12.

Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2215/CJN.03230319DOI Listing

The clinical significance of plasma CFHR 1-5 in lupus nephropathy.

Immunobiology 2019 Apr 3. Epub 2019 Apr 3.

Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders (Xiangya), Xiangya Hospital, Central South University, Changsha 410008, Hunan, China. Electronic address:

A deficiency of complement factor H may lead to excessive consumption of C3 and an increase in C3b deposition, which are important pathological characteristics of lupus nephritis. Complement factor H-related proteins (CFHRs), comprising CFHR1 to CFHR5 (CFHR1-5), are members of the wider factor H/CFHR family. Their role in lupus nephritis remains unclear. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01712985183017
Publisher Site
http://dx.doi.org/10.1016/j.imbio.2019.03.005DOI Listing
April 2019
2 Reads

[Detection of cell-bound immune complexes and its diagnostic value in systemic lupus erythematosus].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2019 Feb;35(2):162-168

Department of Laboratory Medicine, First Affiliated Hospital, Wannan Medical College, Wuhu 241001, China. *Corresponding author, E-mail:

Objective To detect the levels of cell-bound complement activation product (C4d) and immunoglobulins (IgG and IgM) on T and B lymphocytes in patients with systemic lupus erythematosus (SLE), and to evaluate the relationships between C4d and immunoglobulins (Ig) on lymphocytes, and finally to evaluate their diagnostic value for SLE. Methods A cross-sectional study including 142 SLE patients, 144 patients with other non-SLE autoimmune diseases and 100 healthy individuals was conducted. C4d and immunoglobulins on peripheral T and B lymphocytes (T-C4d, B-C4d, T-Ig and B-Ig) were measured by flow cytometry. Read More

View Article

Download full-text PDF

Source
February 2019

An OMICS-based study of the role of C3dg in keratinocytes: RNA sequencing, antibody-chip array, and bioinformatics approaches.

Int J Biol Macromol 2019 Apr 8. Epub 2019 Apr 8.

College of Biological and Environmental Sciences, Zhejiang Wanli University, Ningbo, 315100, PR China; Department of Dermatology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul 135-710, Republic of Korea; Skin Diseases Research Center, Yangtze Delta Region Institute of Tsinghua University, 705 Yatai Road, Jiaxing 314006, PR China. Electronic address:

Previously, we have identified the C3dg protein as an important player in the pathogenesis of atopic dermatitis (AD). In this study, we aimed to identify critical factors associated with C3dg in human keratinocytes based on high-throughput screening (HTS) approaches. We overexpressed C3dg in HaCaT human keratinocytes and conducted serial HTS studies, including RNA sequencing analysis integrated with antibody-chip arrays and implementation of bioinformatics algorithms (PPI mappings). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01418130193188
Publisher Site
http://dx.doi.org/10.1016/j.ijbiomac.2019.04.039DOI Listing
April 2019
5 Reads

Septic shock among patients with systemic lupus erythematosus: short and long-term outcome. Analysis of a French nationwide database.

J Infect 2019 Apr 8. Epub 2019 Apr 8.

APHP Medical and infectious diseases ICU Bichat hospital, F75018, Paris.

Objectives: We aimed to assess the characteristics, outcomes and costs of septic shock complicating Systemic Lupus Erythematosus (SLE).

Methods: Characteristics of SLE patients experiencing a septic shock in France from 2010 to 2015 were analyzed through the French medico-administrative database. Factors associated with the 1-year post-admission mortality were analyzed, the crude 1-year survival of SLE patients experiencing septic shock was compared to those admitted for another reason, and we compared the 1-year outcome associated with SLE septic shock survival to a matched SLE ICU control population. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01634453193011
Publisher Site
http://dx.doi.org/10.1016/j.jinf.2019.04.005DOI Listing
April 2019
5 Reads

Glomerular expression of matrix metalloproteinases in systemic lupus erythematosus in association with activity index and renal function.

Ren Fail 2019 Nov;41(1):229-237

f Department of Nephrology , University Hospital of Alexandroupoli , Alexandroupolis , Greece.

Purpose: The aim of this study was to examine the expression of matrix metalloproteinases (MMPs) MMP-1, MMP-2, MMP-3, MMP-9, and their specific tissue inhibitor TIMP-1 in kidney biopsies of patients with lupus nephritis (LN) and to investigate the relationship between MMPs, activity index, and renal function at the time of kidney biopsy.

Methods: We performed immunohistochemistry with monoclonal antibodies against MMP-1, MMP-2, MMP-3, MMP-9, and TIMP-1 in 58 kidney-biopsy specimens with LN (according to the 2004 ISN/RPS classification) and eight specimens from normal kidney tissue. We used clinical data of 36 patients at the time of kidney biopsy to evaluate the association between MMPs expression and renal function. Read More

View Article

Download full-text PDF

Source
November 2019
1 Read

Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus.

Front Med (Lausanne) 2019 26;6:52. Epub 2019 Mar 26.

Section of Rheumatology, Department of Medical Sciences, University of Ferrara, Azienda Ospedaliero-Universitaria Sant'Anna Ferrara, Ferrara, Italy.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fmed.2019.00052/
Publisher Site
http://dx.doi.org/10.3389/fmed.2019.00052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443841PMC
March 2019
5 Reads

miR-125a-3p decreases levels of interlukin-17 and suppresses renal fibrosis via down-regulating TGF-β1 in systemic lupus erythematosus mediated Lupus nephritic mice.

Am J Transl Res 2019 15;11(3):1843-1853. Epub 2019 Mar 15.

Department of Nephrology, Hanzhong Central Hospital Hanzhong 723000, Shaanxi, China.

Lupus nephritis (LN) is an autoimmune disorder mediated by systemic lupus erythematosus (SLE). Micro RNAs also called as miRs act potentially in the development and progression of SLE. MiR-125a-3p is reported to be down-regulated inpatients of SLE. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456516PMC
March 2019
1 Read

RasGRP3 in peripheral blood mononuclear cells is associated with disease activity and implicated in the development of systemic lupus erythematosus.

Am J Transl Res 2019 15;11(3):1800-1809. Epub 2019 Mar 15.

Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China.

This study examined the relationship between the expression of Ras guanyl nucleotide-releasing protein 3 (RasGRP3) and disease activity in systemic lupus erythematosus (SLE) and explored the possible mechanisms in mice. We detected the expression of RasGRP3 in peripheral blood mononuclear cells (PBMCs) of SLE patients (n=26) and healthy controls (n=20) by employing RT-PCR and studied the association between the mRNA expression of RasGRP3 in PBMCs and the clinical findings. We also measured the protein level of RasGRP3 in PBMCs by Western blotting (n=10). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456560PMC
March 2019
1 Read

Mechanistic insights into environmental and genetic risk factors for systemic lupus erythematosus.

Am J Transl Res 2019 15;11(3):1241-1254. Epub 2019 Mar 15.

Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University Zhanjiang 524001, Guangdong, China.

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organ systems with diverse presentation, primarily affecting women of reproductive age. Various genetic and environmental risk factors are involved in the pathogenesis of SLE, and many SLE susceptibility genes have been identified recently; however, gene therapy is not a viable clinical option at this time. Thus, environmental risks factors, particularly regional characteristics that can be controlled, need to be further investigated. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456562PMC
March 2019
1 Read

Disseminated infection presenting as a paravertebral abscess in a patient with systemic lupus erythematosus.

Indian J Pathol Microbiol 2019 Apr-Jun;62(2):329-331

Department of Infectious Disease and Clinical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey.

Disseminated Nocardia infections occur particularly in immunosuppressed hosts and are most often due to Nocardia farcinica, Nocardia nova, and Nocardia cyriacigeorgica. Here, we report an unusual case of disseminated N. farcinica infection presenting as a paravertebral abscess in a patient with systemic lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_178_17DOI Listing
April 2019
1 Read

Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study.

Lupus 2019 Apr 10:961203319842663. Epub 2019 Apr 10.

1 Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung.

Lupus nephritis (LN) is the leading cause of mortality in lupus patients. This study aimed to investigate the treatment outcome and renal histological risk factors of LN in a tertiary referral center. Between 2006 and 2017, a retrospective observational study enrolled 148 biopsy-proven LN patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319842663DOI Listing
April 2019
1 Read

Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.

Lupus 2019 Apr 10:961203319843343. Epub 2019 Apr 10.

1 Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: Hydroxychloroquine (HCQ) is regarded as a mainstay in the treatment of systemic lupus erythematosus (SLE) because of its efficacy in preventing flares, achieving remission, and reducing overall mortality. However, the impact of HCQ on pregnancy outcomes remains controversial.

Objective: We aimed to investigate the effect of HCQ on pregnancy outcomes in patients with SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0961203319843343DOI Listing
April 2019
4 Reads

Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry.

Int J Rheum Dis 2019 Apr 10. Epub 2019 Apr 10.

Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Background: Inflammatory idiopathic myositis (IIM) comprises a heterogeneous group of systemic muscular diseases that can occur together with other connective tissue diseases (CTD), named overlap myositis (OM). The question of whether OM is a distinct entity still remains controversial.

Aim: The present study was conducted to assess the clinical and prognostic differences between patients diagnosed with OM, primary polymyositis (PM) and primary dermatomyositis (DM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13559DOI Listing
April 2019
1 Read

Mortality prediction in systemic lupus erythematosus patients with pulmonary infection.

Int J Rheum Dis 2019 Apr 10. Epub 2019 Apr 10.

Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, China.

Objective: The impact of pulmonary infection (PI) on mortality of patients with systemic lupus erythematosus (SLE) has been established. Nevertheless, the effect of risk factors in mortality remains controversial. The objective of this study is to determine the risk factors of short-term mortality among SLE patients with PI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13555DOI Listing
April 2019
1 Read

Work disability in a multi-ethnic Malaysian systemic lupus erythematosus cohort: A cross-sectional study.

Int J Rheum Dis 2019 Apr 10. Epub 2019 Apr 10.

Department of Internal Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.

Aim: To determine the prevalence of work disability (WD) among patients with systemic lupus erythematosus (SLE) and its associated factors.

Method: This was a cross-sectional study involving SLE patients aged 18-56 years from Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Employment history was obtained from clinical interviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13572DOI Listing
April 2019
1 Read

MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus.

Front Immunol 2019 22;10:538. Epub 2019 Mar 22.

Laboratory of Immunobiology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.

Systemic Lupus Erythematosus (SLE) is a common and devastating autoimmune disease, characterized by a dysregulated adaptive immune response against intracellular antigens, which involves both autoreactive T and B cells. In SLE, mainly intracellular autoantigens generate autoantibodies and these assemble into immune complexes and activate the classical pathway of the complement system enhancing inflammation. Matrix metalloproteinase-9 (MMP-9) levels have been investigated in the serum of SLE patients and in control subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440319PMC
March 2019
1 Read

DPP-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.

Br J Clin Pharmacol 2019 Apr 9. Epub 2019 Apr 9.

College of Pharmacy and Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.

Aims: To evaluate the real-world effect of DPP-4 inhibitor (DPP4i) on the incidence of autoimmune diseases (AD), including rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), multiple sclerosis (MS), and systemic lupus erythematosus (SLE).

Methods: We identified new users of DPP4i (N=497 619) or non-DPP4i (N=643 165) oral combination therapy between 1 January 2011 and 30 June 2015 among patients with type 2 diabetes mellitus in the Korean national health insurance claims database. Patients were followed from the date of initiation of combination therapy until AD outcome, censoring for treatment discontinuation or switching, death or end of study (31 August 2016). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13955DOI Listing
April 2019
1 Read

Burden of comorbidities in South Africans with systemic lupus erythematosus.

Clin Rheumatol 2019 Apr 8. Epub 2019 Apr 8.

Division of Rheumatology, Chris Hani Baragwanath Academic Hospital and University of the Witwatersrand, P.O. Bertsham, Johannesburg, 2013, South Africa.

Introduction: To investigate the prevalence and spectrum of comorbidities in South Africans with systemic lupus erythematosus (SLE).

Patients And Methods: A nested case-control study of a known alive group (AG) and deceased group (DG) of 200 and 40 patients, respectively, matched for age and sex, attending a tertiary Lupus Clinic. Comorbidities that were documented included, but not restricted to, those listed in the Charlson comorbidity index (CCI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-019-04511-7DOI Listing
April 2019
1 Read

Challenging Diagnostics of Biofilm Associated Periprosthetic Infection in Immunocompromised Patient: A Clinical Case.

Open Access Maced J Med Sci 2019 Mar 13;7(5):786-790. Epub 2019 Mar 13.

Russian Ilizarov Scientific Center for Restorative Traumatology and Orthopaedics, Kurgan, Kurgan Oblast, Russia.

Background: Periprosthetic joint infection (PJI) is a devastating complication of joint arthroplasty. The identification of microorganisms in biofilm-related PJI is challenging yet significant stage of the treatment process. Medical microbiology methods, such as pure culture isolation, remain the gold standard. Read More

View Article

Download full-text PDF

Source
https://www.id-press.eu/mjms/article/view/oamjms.2019.180
Publisher Site
http://dx.doi.org/10.3889/oamjms.2019.180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447350PMC
March 2019
1 Read

Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy.

J Exp Med 2019 Apr 8. Epub 2019 Apr 8.

Drukier Institute for Children's Health, Weill Cornell Medicine, New York, NY.

Systemic lupus erythematosus carries an increased risk of pregnancy complications, including preeclampsia and fetal adverse outcomes. To identify the underlying molecular mechanisms, we longitudinally profiled the blood transcriptome of 92 lupus patients and 43 healthy women during pregnancy and postpartum and performed multicolor flow cytometry in a subset of them. We also profiled 25 healthy women undergoing assisted reproductive technology to monitor transcriptional changes around embryo implantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20190185DOI Listing
April 2019
6 Reads
12.515 Impact Factor